NCT03065387 2026-01-12Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationM.D. Anderson Cancer CenterPhase 1 Active not recruiting93 enrolled
NCT06083662 2025-03-18Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid CancersKorea University Guro HospitalPhase 2 Completed42 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled